TY - JOUR T1 - Cervical Cancer Patient-Derived Orthotopic Xenograft (PDOX) Is Sensitive to Cisplatinum and Resistant to Nab-paclitaxel JF - Anticancer Research JO - Anticancer Res SP - 61 LP - 65 VL - 37 IS - 1 AU - TAKASHI MURAKAMI AU - TAKUYA MURATA AU - KEI KAWAGUCHI AU - TASUKU KIYUNA AU - KENTARO IGARASHI AU - HO KYOUNG HWANG AU - YUKIHIKO HIROSHIMA AU - CHIHIRO HOZUMI AU - SHIN KOMATSU AU - TAKASHI KIKUCHI AU - THINZAR M. LWIN AU - JONATHAN C. DELONG AU - KENTARO MIYAKE AU - YONG ZHANG AU - KUNIYA TANAKA AU - MICHAEL BOUVET AU - ITARU ENDO AU - ROBERT M. HOFFMAN Y1 - 2017/01/01 UR - http://ar.iiarjournals.org/content/37/1/61.abstract N2 - Background: Cervical cancer is a world-wide problem that requires transformative therapeutic strategies. We have previously developed patient-derived orthotopic xenograft (PDOX) nude-mouse models of this disease. In the present report, we demonstrate that the standard drug, cisplatinum (CDDP), is highly-effective while the new, highly-touted agent, nab-paclitaxel (NAB-PTX) is ineffective. Materials and Methods: Cervical PDOX tumors were grown on the cervix of nude mice for 4 weeks after surgical orthotopic implantation (SOI). Tumors were treated with CDDP or NAB-PTX. Results: H&E staining demonstrated that the PDOX tumor recapitulated the original patient tumor. CDDP was highly-effective. One tumor that was treated with CDDP completely regressed. CDDP-treated tumors were smaller (tumor volume ratio: 0.42±0.36) than the control group (tumor volume ratio: 3.47±1.66) (p<0.01). In contrast, NAB-PTX did not show significant efficacy on the cervical cancer PDOX model (tumor volume ratio: 2.85±1.45) (p=0.47). CDDP-treated tumor weight (50±50 mg) was significantly less than control (238±114 mg) (p<0.01). NAB-PTX-treated tumors were not reduced in weight (246±136 mg) compared to control (p=0.91). There were no significant differences in mouse body weight between groups. Histological evaluation demonstrated that CDDP-treated tumors were fibrotic with scattered squamous cell nests compared to control or NAB-PTX-treated tumors. Conclusion: The results of the present study demonstrate the power of PDOX models of cervical cancer to distinguish efficacy of potential therapeutics for individual patients with this disease. ER -